AAA
KRTX

Affinity Asset Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Affinity Asset Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,500
Closed -$2.27M – 92
2023
Q1 		$2.27M Buy
+12,500
New +$2.39M 0.75% 40
2022
Q3 		– Sell
-45,000
Closed -$5.69M – 82
2022
Q2 		$5.69M Buy
45,000
+37,500
+500% +$4.31M 2.4% 13
2022
Q1 		$951K Buy
+7,500
New +$844K 0.15% 47

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Asset Advisors's KRTX Position: Q2 2023 in Review

Affinity Asset Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 12,500 shares — an estimated $2.27M sold.

Affinity Asset Advisors first reported a position in KRTX in Q1 2022 and held it in 3 quarters. The position peaked at $5.69M in Q2 2022. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Affinity Asset Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Affinity Asset Advisors sold 12,500 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.27M.
  • Affinity Asset Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Affinity Asset Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $5.69M in Q2 2022.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.